Open Label, Phase II Study with Anakinra in Intravenous Immunoglobulin‐Resistant Kawasaki Disease

Small uncontrolled study in 16 patients found that 75% of patients became afebrile within 48 hours, and reduction of disease activity by 50% was reached by 93.3% based on physician’s evaluation.

Arthritis & Rheumatology